


Summary of results for people (women and men) diagnosed with primary breast cancer (stage 0 to 3) in England and Wales between 1st January 2020 and 31st December 2022.

Key: E England W Wales

Total: 134,161 women and 954 men diagnosed 2020-2022

E **England: 127,966**
(127,054 women and 912 men)

W **Wales: 7,149**
(7,017 women and 42 men)




Triple Diagnostic Assessment

68% of patients in England* and 51% in Wales underwent Triple Diagnostic Assessment — meaning they received clinical assessment, imaging, and biopsy during a single hospital visit leading to their diagnosis.




Surgery

Among those who had surgery within 12 months of diagnosis, 73% of people in England and 69% in Wales had Breast Conserving Surgery as their first surgery. The rest of individuals had mastectomy (lighter boxes) as their primary surgery.




Neo-Adjuvant Chemotherapy (NACT)

Among patients with stage 2 to 3A triple negative or HER2 positive breast cancer who underwent surgery within 12 months of diagnosis, 52% in England and 32% in Wales received neo- adjuvant chemotherapy (chemotherapy before surgery).




Immediate Breast Reconstruction

Among women who had a mastectomy, 24% in England and 13% in Wales underwent immediate breast reconstruction at the time of their mastectomy, with marked variation observed between different organisations.



Re-operation

Within 12 months of initial breast-conserving surgery, 16% of individuals in England and 20% in Wales required at least one re-operation. Again, marked variation was observed between different organisations.




Clinical Nurse Specialist (CNS) Contact

For those with data available, 94% of people in England and 82% in Wales had contact with a CNS after diagnosis. However, data completeness was 78% for England and 93% for Wales.



Survival

Among individual diagnosed with primary breast cancer (Stage 1 to 3A) in England and Wales, 3-year all-cause survival was 92%. 3-year breast cancer-specific survival was 97%.



* Data field for triple diagnostic assessment for England was not mature enough for use in this report. An algorithm was applied to estimate this for England. Details can be found in the methodology supplement.